The results showed that patients receiving on-demand therapy experienced a significantly greater number of bleeds than those patients in the prophylaxis group.
NHLB is currently seeking feedback on hemophilia inhibitors measures proposed for inclusion in the PhenX Toolkit (consensus measures for Phenotypes and eXposures).
The International Society on Thrombosis and Hemostasis (ISTH) recently developed a new tool to help clinicians identify and measure the severity of bleeding symptoms.
Researchers from the University of California (UC) Davis have been investigating whether two genetically engineered cell types could be customized for long term therapeutic benefit in individuals with hemophilia A.
The data presented was from 33 patients who have completed five years of treatment with Jivi®.
The data from both studies confirmed the safety and sustained efficacy of Eloctate ® and Alprolix ® over four years of treatment.
The two recommendations address gene therapy clinical trials, and use of emicizumab-kxwh.
This chapter includes new product approvals and Guelcher explains that ITI could be the solution to eradicate the inhibitor itself.
NHF, Impact Education and the Postgraduate Institute for Medicine offers accredited educational opportunties for healthcare providers on managing and treating females with bleeding disorders.
The Genentech therapy has been approved for routine prophylaxis in adults and children with or without factor VIII inhibitors.
eNewsletter Sign Up
Steps for Living
Victory for Women
Unite for Bleeding Disorders Walk
Donate Your Car